Bayer has entered into a licence agreement with Daré Bioscience to commercialise investigational contraceptive product called Ovaprene in the US.
14 Jan 2020
03 Jan 2020
US-based Amgen has closed the acquisition of a 20.5% stake in Chinese biopharmaceutical firm BeiGene for approximately $2.8bn to support the expansion of its oncology footprint in China.
02 Jan 2020
GlaxoSmithKline (GSK) has completed the sale of its travel vaccines Rabipur for rabies, and Encepur for tick-borne encephalitis, to Bavarian Nordic.
17 Dec 2019
AstraZeneca closes deal with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia
AstraZeneca has completed an agreement to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm).
11 Dec 2019
Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.
04 Dec 2019
AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.
27 Nov 2019
Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.
12 Nov 2019
Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).
07 Nov 2019
Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.
31 Oct 2019
AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.